Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Change in Accured Expenses (2020 - 2025)

Ovid Therapeutics' Change in Accured Expenses history spans 6 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 229.55% year-over-year to $2.1 million; the TTM value through Dec 2025 reached -$1.1 million, down 98.88%, while the annual FY2025 figure was -$1.1 million, 98.88% down from the prior year.
  • Change in Accured Expenses reached $2.1 million in Q4 2025 per OVID's latest filing, up from $27000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.1 million in Q2 2024 to a low of -$3.4 million in Q3 2021.
  • Average Change in Accured Expenses over 5 years is -$355600.8, with a median of $13000.0 recorded in 2025.
  • Peak YoY movement for Change in Accured Expenses: crashed 622.77% in 2024, then surged 229.55% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $748263.0 in 2021, then tumbled by 259.64% to -$1.2 million in 2022, then soared by 125.36% to $303000.0 in 2023, then plummeted by 622.77% to -$1.6 million in 2024, then soared by 229.55% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Change in Accured Expenses are $2.1 million (Q4 2025), $27000.0 (Q3 2025), and -$3.1 million (Q2 2025).